Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Bugelski

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Infection and Immunity|February 13, 2001
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic miceD J Herzyk, E R Gore, R Polsky, et al.
Journal of Virology|September 1, 1995
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cellsC C LaBranche, M M Sauter, B S Haggarty, et al.
Journal of Clinical Immunology|March 1, 1996
Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various speciesE V Ruggieri, P J Bugelski, J M Kaplan, et al.
Antimicrobial Agents and Chemotherapy|May 11, 1992
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsD M Lambert, S R Petteway, C E McDanal, et al.
Journal of Biotechnology|February 5, 2008
CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in miceP J Bugelski, R J Capocasale, D Makropoulos, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2001
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysT K Hart, R M Cook, P Zia-Amirhosseini, et al.
Human & Experimental Toxicology|August 3, 2000
Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studiesP J Bugelski, D J Herzyk, S Rehm, et al.
Clinical Immunology (Orlando, Fla.)|February 13, 2001
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzeesR Newman, K Hariharan, M Reff, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Infection and Immunity|February 13, 2001
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic miceD J Herzyk, E R Gore, R Polsky, et al.
Journal of Virology|September 1, 1995
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cellsC C LaBranche, M M Sauter, B S Haggarty, et al.
Journal of Clinical Immunology|March 1, 1996
Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various speciesE V Ruggieri, P J Bugelski, J M Kaplan, et al.
Antimicrobial Agents and Chemotherapy|May 11, 1992
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsD M Lambert, S R Petteway, C E McDanal, et al.
Journal of Biotechnology|February 5, 2008
CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in miceP J Bugelski, R J Capocasale, D Makropoulos, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2001
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysT K Hart, R M Cook, P Zia-Amirhosseini, et al.
Human & Experimental Toxicology|August 3, 2000
Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studiesP J Bugelski, D J Herzyk, S Rehm, et al.
Clinical Immunology (Orlando, Fla.)|February 13, 2001
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzeesR Newman, K Hariharan, M Reff, et al.
Pageof 7